Elevance Health, Inc. $ELV is Artisan Partners Limited Partnership’s 8th Largest Position

Artisan Partners Limited Partnership increased its stake in Elevance Health, Inc. (NYSE:ELV) by 24.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,576,805 shares of the company’s stock after purchasing an additional 901,626 shares during the quarter. Elevance Health makes up approximately 2.1% of Artisan Partners Limited Partnership’s portfolio, making the stock its 8th biggest holding. Artisan Partners Limited Partnership owned 2.06% of Elevance Health worth $1,478,857,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Physician Wealth Advisors Inc. lifted its position in shares of Elevance Health by 331.6% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock valued at $26,000 after buying an additional 63 shares during the last quarter. Activest Wealth Management increased its holdings in Elevance Health by 66.7% in the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after acquiring an additional 34 shares during the last quarter. Rossby Financial LCC raised its stake in Elevance Health by 110.0% in the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock valued at $28,000 after acquiring an additional 44 shares during the period. Vermillion & White Wealth Management Group LLC lifted its holdings in Elevance Health by 94.9% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock valued at $30,000 after purchasing an additional 37 shares during the last quarter. Finally, BOK Financial Private Wealth Inc. bought a new position in Elevance Health during the second quarter worth about $32,000. 89.24% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Guggenheim lowered their price target on shares of Elevance Health from $414.00 to $396.00 and set a “buy” rating on the stock in a research report on Thursday, January 29th. Zacks Research upgraded shares of Elevance Health from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 6th. Leerink Partners increased their target price on Elevance Health from $350.00 to $357.00 and gave the stock a “market perform” rating in a research report on Thursday, January 29th. Weiss Ratings lowered Elevance Health from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, February 2nd. Finally, Barclays reduced their price target on Elevance Health from $404.00 to $393.00 and set an “overweight” rating for the company in a research report on Friday, January 30th. Twelve investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $390.55.

Elevance Health Stock Performance

NYSE ELV opened at $322.94 on Friday. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $458.75. The company has a fifty day moving average of $350.62 and a 200-day moving average of $335.19. The company has a market capitalization of $71.28 billion, a P/E ratio of 12.86, a P/E/G ratio of 1.83 and a beta of 0.50. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 1.54.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The business had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. During the same quarter last year, the business posted $3.84 earnings per share. The company’s revenue for the quarter was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, equities research analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be given a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date is Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio is presently 27.23%.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.